Study Shows Higher Survival With Revlimid And Low-Dose Dexamethasone Than Revlimid And High-Dose Dexamethasone In Multiple Myeloma Patients
A recent study of newly diagnosed multiple myeloma patients found that Revlimid (lenalidomide) and low-dose dexamethasone (Decadron) resulted in better short-term overall survival and fewer severe side effects than Revlimid and high-dose dexamethasone. Results were so convincing after one year that the trial was stopped early.
For years, Revlimid plus high-dose dexamethasone has been a standard treatment for multiple myeloma.
“The results of the study have already changed practice worldwide,” said Dr. S. Vincent Rajkumar of the Mayo Clinic and lead author of the study.
In this study, 445 patients were randomly assigned to receive either a high- or low-dose treatment over four 28-day cycles. After the four cycles, a complete or partial response was seen in 169 of the eligible 214 high-dose patients (79 percent) and in 142 of the eligible 205 low-dose patients (68 percent).
After one year, overall survival was 96 percent in the low-dose group and 87 percent in the high-dose group. As a result, the trial was prematurely terminated and patients in the high-dose group were switched to the low-dose treatment.
Within the first four cycles, 117 high-dose patients (52 percent) experienced severe side effects compared to only 76 low-dose patients (35 percent).
The most common severe side effects were deep vein thrombosis, pneumonia, and fatigue. Deep vein thrombosis, or blood clotting in veins located deep in the body, was reported in 26 percent of high-dose patients and 12 percent of low-dose patients; pneumonia was seen in 16 percent and 9 percent, respectively; and fatigue was experienced by 15 percent and 9 percent, respectively.
According to Dr. Rajkumar, not only does low-dose dexamethasone result in fewer side effects, but it likely allows patients to be treated for longer, which translates into a beneficial clinical effect.
Greater survival with low-dose dexamethasone might also be due to high-dose dexamethasone countering some of the favorable effects of Revlimid, he said.
The study has had a significant impact on the multiple myeloma community. “Very few patients receive high-dose dexamethasone anymore, particularly in the newly diagnosed setting, and most if not all currently ongoing Phase 3 trials are using low-dose dexamethasone,” said Dr. Rajkumar.
“I believe that the results of the study have already made life easier and more tolerable for patients and also lowered early mortality significantly.”
For more information, please see the study in The Lancet Oncology (abstract).
Related Articles:
- None Found
I was diagnosed in 2006 with multiple myeloma with light chain. Have relapsed in Sept. 2009 after múltiple txs including two stem cell autologous transplants and two years in remission. Noé The mm has moved to my bones. Having radiation 5 sessions for plasmocytoma in headi pushing vs. membane of brain. Tumor broke thru bone and appeared mushroom-shaped. Two on right ribs - paiful. Prescribed high dosage dex (40) and (10) revlimid -exp. Severe side effects - fatigue, gastrointestinal pain, nausea, hallucinations, rapid out of control thoughts, high blood pressure, palpitations, inability to sleep (3 days after) dex. Oncologist working on next protocol. Am excited by study. Would like to know how to contact authot of study? Who else is doing same? Similar ? I am in VA. Treated at The Stony Point Medical college of VA Cancer Center.
Thank you for your comment, Dr. Muguira. The lead author’s contact information can be found in the published abstract. A link to the abstract is also provided at the end of the article. For information about similar studies as well as those in your area, please consult clinicaltrials.gov.
Best,
Joanna Mandecki
Were any of the patients given a stem cell transplant after one 4 week cycle and, if so, how did they fare, low-dose vs. high-dose?
Yes, 167 patients stopped treatment after one cycle to undergo stem cell harvesting. The study reports that 163 (98 percent) were successful and four (2 percent) were unsuccessful. More details, including a breakdown of low-dose vs. high-dose patients, are not provided.
My father has just been prescribed Revlimid for his multiple myeloma and paniced when he found out how much it would cost. He has medicare as his primary and tricare standard as his secondary insurance. Is any of the cost covered by insurance? Any suggestions?
You may find Celgene's patient support program helpful: http://www.revlimid.com/multiple-myeloma/multiple-myeloma-psc.aspx. I would also suggest consulting a physician for more information about treatment options and coverage.
Get new Myeloma Beacon articles by email.